A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-03. Anything still debated is marked as such rather than presented as settled.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
The primary form of fixed inorganic carbon is carbon dioxide (CO2). It is estimated that approximately 250 billion tons of carbon dioxide are converted by photosynthesis annually, nearly one half in the oceans and a bit more in terrestrial environments. The majority of the fixation in terrestrial environments occurs in the tropics. The gross amount of carbon dioxide fixed is much larger since approximately 40% is consumed by respiration following photosynthesis. Historically, it is estimated that approximately 2×1011 billion tons of carbon has been fixed since the origin of life.
=== Irreversible pulpitis === Pulpitis is established when the pulp chamber is compromised by bacterial infection. Irreversible pulpitis is diagnosed when the pulp is inflamed and infected beyond healing. Removal of the aetiological agent does not permit healing, and a root canal is often indicated. Irreversible pulpitis follows reversible pulpitis absent early intervention. While the pulp is still vital and vascularised, it is not classified as 'dead pulp'. Irreversible and reversible pulpitis are distinguished by the pain responses to thermal stimulation. If the condition is reversible, the pulp's pain response lasts a few seconds upon exposure to cold or hot. If the pain lingers from minutes to hours, the condition is classified as irreversible. This is a common presenting complaint that facilitates initial diagnosis. Irreversible puplitis may be symptomatic or asymptomatic. Asymptomatic irreversible pulpitis results from transition of symptomatic irreversible pulpitis into an inactive/quiescent state. This is due to its aetiology; inflammatory exudate can be quickly removed, e.g. through a large carious cavity or previous trauma that caused painless pulp exposure. The build-up of pressure in a confined pulp space initiates pain reflexes. When this pressure is relieved, pain subsides. As the names imply, these diseases are largely characterised by their symptoms: pain duration and location, and exacerbating and relieving factors.
=== Marketing of opioid painkillers === In July 2022 the company agreed to pay up to $2.37 billion to settle U.S. lawsuits against its Allergan unit over the marketing of opioid analgesics. AbbVie denied any wrongdoing.
Sources: en.wikipedia.org
These included an 1870 plan for new armory for the 7th New York Militia, an 1880 plan for an opera house, another plan in 1881 for a New York Historical Society building, an 1893 plan for relocating the New York City Hall building, and a 1903 plan for a general post office.
2020, A. T. Williams, C. R. Muller, A. M. Eaker, D. A. Belcher, C. Bolden-Rush, A. F. Palmer, P. Cabrales, “Polymerized hemoglobin with increased molecular size reduces toxicity in healthy guinea pigs,” ACS Applied Bio Materials Apr 14 3, 5:2976–2985. 2020, A. T. Williams, A. Lucas, C. R. Muller, C. Bolden-Rush, A. F. Palmer, P. Cabrales, “Balance between oxygen transport and blood rheology during resuscitation from hemorrhagic shock with polymerized hemoglobin,” Journal of Applied Physiology Jul 1;129(1):97-107. 2021, C. R. Muller, A. Lucas, V. Courelli, A. T. Williams, F. Dos Santos, C. Cuddington, S. Moses, A. F. Palmer, E. Kistler, P. Cabrales, “Resuscitation from hemorrhagic shock after traumatic brain injury with polymerized hemoglobin,” Scientific Reports Jan 28;11(1):2509. Facilitated oxygen transport Palmer's research focuses on approaches to better improve oxygen storage and transport to cultured cells, especially cells grown in bioreactors. Supporting Publications:
=== Close states === The seven swing states in the 2024 election were the Rust Belt states of Wisconsin, Michigan, and Pennsylvania, as well as the Sun Belt states of Arizona, Georgia, Nevada, and North Carolina. States where the margin of victory was under 1 percentage point (10 electoral votes; all won by Trump):
EC 1.14.14.5: alkanesulfonate monooxygenase EC 1.14.14.6: Now EC 1.14.13.111, methanesulfonate monooxygenase EC 1.14.14.7: transferred to EC 1.14.19.9, tryptophan 7-halogenase EC 1.14.14.8: anthranilate 3-monooxygenase (FAD) EC 1.14.14.9: 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.14.10: nitrilotriacetate monooxygenase EC 1.14.14.11: styrene monooxygenase EC 1.14.14.12: 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione monooxygenase EC 1.14.14.13: 4-(γ-L-glutamylamino)butanoyl-[BtrI acyl-carrier protein] monooxygenase EC 1.14.14.14: aromatase EC 1.14.14.15: (3S)-3-amino-3-(3-chloro-4-hydroxyphenyl)propanoyl-[peptidyl-carrier protein SgcC2] monooxygenase EC 1.14.14.16: steroid 21-monooxygenase EC 1.14.14.17: squalene monooxygenase EC 1.14.14.18: heme oxygenase (biliverdin-producing) EC 1.14.14.19: steroid 17α-monooxygenase EC 1.14.14.20: phenol 2-monooxygenase (FADH2) EC 1.14.14.21: dibenzothiophene monooxygenase EC 1.14.14.22: dibenzothiophene sulfone monooxygenase EC 1.14.14.23: cholesterol 7α-monooxygenase EC 1.14.14.24: vitamin D 25-hydroxylase EC 1.14.14.25: cholesterol 24-hydroxylase EC 1.14.14.26: 24-hydroxycholesterol 7α-hydroxylase EC 1.14.14.27: resorcinol 4-hydroxylase (FADH2) EC 1.14.14.28: long-chain alkane monooxygenase EC 1.14.14.29: 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.14.30: isobutylamine N-monooxygenase EC 1.14.14.31: ipsdienol synthase EC 1.14.14.32: 17α-hydroxyprogesterone deacetylase EC 1.14.14.33: ethylenediaminetetraacetate monooxygenase EC 1.14.14.34: methanesulfonate monooxygenase (FMNH2) EC 1.14.14.35: dimethylsulfone monooxygenase EC 1.14.14.36: tyrosine N-monooxygenase EC 1.14.14.37: 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.14.38: valine N-monooxygenase EC 1.14.14.39: isoleucine N-monooxygenase EC 1.14.14.40: phenylalanine N-monooxygenase EC 1.14.14.41: (E)-2-methylbutanal oxime monooxygenase EC 1.14.14.42: homomethionine N-monooxygenase EC 1.14.14.43: (methylsulfanyl)alkanaldoxime N-monooxygenase EC 1.14.14.44: phenylacetaldehyde oxime monooxygenase EC 1.14.14.45: aromatic aldoxime N-monooxygenase EC 1.14.14.46: pimeloyl-[acyl-carrier protein] synthase EC 1.14.14.47: nitric-oxide synthase (flavodoxin) EC 1.14.14.48: jasmonoyl-L-amino acid 12-hydroxylase EC 1.14.14.49: 12-hydroxyjasmonoyl-L-amino acid 12-hydroxylase EC 1.14.14.50: tabersonine 3-oxygenase EC 1.14.14.51: (S)-limonene 6-monooxygenase EC 1.14.14.52: (S)-limonene 7-monooxygenase EC 1.14.14.53: (R)-limonene 6-monooxygenase EC 1.14.14.54: phenylacetate 2-hydroxylase EC 1.14.14.55: quinine 3-monooxygenase EC 1.14.14.56: 1,8-cineole 2-exo-monooxygenase EC 1.14.14.57: taurochenodeoxycholate 6α-hydroxylase EC 1.14.14.58: trimethyltridecatetraene synthase EC 1.14.14.59: dimethylnonatriene synthase EC 1.14.14.60: ferruginol monooxygenase EC 1.14.14.61: carnosic acid synthase EC 1.14.14.62: salviol synthase EC 1.14.14.63: β-amyrin 16β-monooxygenase EC 1.14.14.64: β-amyrin 6β-monooxygenase EC 1.14.14.65: sugiol synthase EC 1.14.14.66: marmesin synthase EC 1.14.14.67: 11-hydroxysugiol 20-monooxygenase EC 1.14.14.68: syn-pimaradiene 3-monooxygenase EC 1.14.14.69: ent-cassadiene hydroxylase EC 1.14.14.70: ent-sandaracopimaradiene 3-hydroxylase EC 1.14.14.71: cucurbitadienol 11-hydroxylase EC 1.14.14.72: drimenol monooxygenase EC 1.14.14.73: albendazole monooxygenase (sulfoxide-forming) EC 1.14.14.74: albendazole monooxygenase (hydroxylating) EC 1.14.14.75: fenbendazole monooxygenase (4′-hydroxylating) EC 1.14.14.76: ent-isokaurene C2/C3-hydroxylase EC 1.14.14.77: phenylacetonitrile α-monooxygenase EC 1.14.14.78: phylloquinone ω-hydroxylase EC 1.14.14.79: docosahexaenoic acid ω-hydroxylase EC 1.14.14.80: long-chain fatty acid ω-monooxygenase EC 1.14.14.81: flavanoid 3′,5′-hydroxylase EC 1.14.14.82: flavonoid 3′-monooxygenase EC 1.14.14.83: geraniol 8-hydroxylase EC 1.14.14.84: linalool 8-monooxygenase EC 1.14.14.85: 7-deoxyloganate 7-hydroxylase EC 1.14.14.86: ent-kaurene monooxygenase EC 1.14.14.87: 2-hydroxyisoflavanone synthase EC 1.14.14.88: isoflavone 3′-hydroxylase EC 1.14.14.89: 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.14.90: isoflavone 2′-hydroxylase EC 1.14.14.91: trans-cinnamate 4-monooxygenase EC 1.14.14.92: benzoate 4-monooxygenase EC 1.14.14.93: 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.14.94: leukotriene-B4 20-monooxygenase EC 1.14.14.95: germacrene A hydroxylase EC 1.14.14.96: 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.14.97: methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.14.98: protopine 6-monooxygenase EC 1.14.14.99: (S)-limonene 3-monooxygenase EC 1.14.14.100: dihydrosanguinarine 10-monooxygenase EC 1.14.14.101: dihydrochelirubine 12-monooxygenase EC 1.14.14.102: N-methylcoclaurine 3′-monooxygenase EC 1.14.14.103: tabersonine 16-hydroxylase EC 1.14.14.104: vinorine hydroxylase EC 1.14.14.105: taxane 10β-hydroxylase EC 1.14.14.106: taxane 13α-hydroxylase EC 1.14.14.107: ent-kaurenoic acid monooxygenase EC 1.14.14.108: 2,5-diketocamphane 1,2-monooxygenase EC 1.14.14.109: 3-hydroxyindolin-2-one monooxygenase EC 1.14.14.110: 2-hydroxy-1,4-benzoxazin-3-one monooxygenase EC 1.14.14.111: 9β-pimara-7,15-diene oxidase EC 1.14.14.112: ent-cassa-12,15-diene 11-hydroxylase EC 1.14.14.113: α-humulene 10-hydroxylase EC 1.14.14.114: amorpha-4,11-diene 12-monooxygenase EC 1.14.14.115: 11-oxo-β-amyrin 30-oxidase EC 1.14.14.116: averantin hydroxylase EC 1.14.14.117: aflatoxin B synthase EC 1.14.14.118: tryprostatin B 6-hydroxylase EC 1.14.14.119: fumitremorgin C monooxygenase EC 1.14.14.120: dammarenediol 12-hydroxylase EC 1.14.14.121: protopanaxadiol 6-hydroxylase EC 1.14.14.122: oryzalexin E synthase EC 1.14.14.123: oryzalexin D synthase EC 1.14.14.124: dihydromonacolin L hydroxylase EC 1.14.14.125: monacolin L hydroxylase EC 1.14.14.126: β-amyrin 28-monooxygenase EC 1.14.14.127: methyl farnesoate epoxidase EC 1.14.14.128: farnesoate epoxidase EC 1.14.14.129: long-chain acyl-CoA ω-monooxygenase EC 1.14.14.130: laurate 7-monooxygenase EC 1.14.14.131: bursehernin 5′-monooxygenase EC 1.14.14.132: (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.14.133: 1,8-cineole 2-endo-monooxygenase EC 1.14.14.134: β-amyrin 24-hydroxylase EC 1.14.14.135: glyceollin synthase EC 1.14.14.136: deoxysarpagine hydroxylase EC 1.14.14.137: (+)-abscisic acid 8′-hydroxylase EC 1.14.14.138: lithocholate 6β-hydroxylase EC 1.14.14.139: 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.14.140: Now included with EC 1.14.14.162 EC 1.14.14.162, flavanone 2-hydroxylase EC 1.14.14.141: psoralen synthase EC 1.14.14.142: 8-dimethylallylnaringenin 2′-hydroxylase EC 1.14.14.143: (+)-menthofuran synthase EC 1.14.14.144: abieta-7,13-diene hydroxylase EC 1.14.14.145: abieta-7,13-dien-18-ol hydroxylase EC 1.14.14.146: geranylgeraniol 18-hydroxylase EC 1.14.14.147: 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.14.148: angelicin synthase EC 1.14.14.149: 5-epiaristolochene 1,3-dihydroxylase EC 1.14.14.150: costunolide synthase EC 1.14.14.151: premnaspirodiene oxygenase EC 1.14.14.152: β-amyrin 11-oxidase EC 1.14.14.153: indole-2-monooxygenase EC 1.14.14.154: sterol 14α-demethylase EC 1.14.14.155: 3,6-diketocamphane 1,2-monooxygenase EC 1.14.14.156: tryptophan N-monooxygenase EC 1.14.14.157: indolin-2-one monooxygenase EC 1.14.14.158: carotenoid ε hydroxylase EC 1.14.14.159: dolabradiene monooxygenase EC 1.14.14.160: zealexin A1 synthase EC 1.14.14.161: nepetalactol monooxygenase EC 1.14.14.162: flavanone 2-hydroxylase EC 1.14.14.163: (S)-1-hydroxy-N-methylcanadine 13-hydroxylase EC 1.14.14.164: fraxetin 5-hydroxylase EC 1.14.14.165: indole-3-carbonyl nitrile 4-hydroxylase EC 1.14.14.166: (S)-N-methylcanadine 1-hydroxylase EC 1.14.14.167: (13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine 8-hydroxylase EC 1.14.14.168: germacrene A acid 8β-hydroxylase EC 1.14.14.169: eupatolide synthase EC 1.14.14.170: 8-epi-inunolide synthase EC 1.14.14.171: β-amyrin 16α-hydroxylase EC 1.14.14.172: 3,5,6-trichloropyridin-2-ol monooxygenase EC 1.14.14.173: 2,4,6-trichlorophenol monooxygenase EC 1.14.14.174: geranylhydroquinone 3′′-hydroxylase EC 1.14.14.175: ferruginol synthase EC 1.14.14.176: taxadiene 5α-hydroxylase EC 1.14.14.177: ultra-long-chain fatty acid ω-hydroxylase EC 1.14.14.182: taxoid 7beta-hydroxylase EC 1.14.14.197: progesterone 11alpha-monooxygenase
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.